Hematology
Conference Coverage
Deferiprone noninferior to deferoxamine for iron overload in SCD, rare anemias
An oral iron chelator granted accelerated approval for thalassemia is noninferior to deferoxamine for iron overload in patients with sickle cell...
From the Journals
Occult HCV infection is correlated to unfavorable genotypes in hemophilia patients
Unfavorable interferon gentoypes were correlated to occult HCV infection in paitents with hemophilia.
Conference Coverage
Bariatric surgery candidates show high prevalence of thrombophilia
LAS VEGAS –
Conference Coverage
BCL11A-directed gene therapy advances in sickle cell disease
ORLANDO – A phase 2/3 study is planned to assess the gene therapy in a larger group of patients with sickle cell disease.
Conference Coverage
ASH releases guidelines on managing cardiopulmonary and kidney disease in SCD
ORLANDO – ASH has released the first of five new sets of sickle cell disease guidelines, with the first focusing on screening and management of...
Conference Coverage
Phase 2 studies show potential of FcRn blockade in primary ITP
ORLANDO – The results support continued investigation in phase 3 trial for rozanolixizumab and efgartigimod, according to investigators.
Conference Coverage
Sutimlimab boosts hemoglobin, quality of life in cold agglutinin disease
ORLANDO – A novel antibody targeted to the complement pathway increased hemoglobin and improved quality of life in patients with cold agglutinin...
Conference Coverage
New ASH guideline: VTE prophylaxis after major surgery
ORLANDO – The chair of VTE guidelines panel presented highlights of the latest guidelines in a special session at the annual meeting of the...
Conference Coverage
NFIX could be a target for sickle cell therapy
ORLANDO – Preclinical research suggests it may be a fetal hemoglobin repressor.
Conference Coverage
Study halted; ‘hyperprogression’ seen with nivolumab for R/R PTCL
ORLANDO –
News from the FDA/CDC
FDA approves Oxbryta for sickle cell disease treatment
The drug, which is approved for adults and children aged 12 years and older, improved hemoglobin in the HOPE trial.